Gilead and Lyndra co-develop long-acting HIV therapies

By Vassia Barba

- Last updated on GMT

(Image: Getty/Marchmeena29)
(Image: Getty/Marchmeena29)

Related tags: Gilead, Lyndra Therapeutics, Hiv

Following Gilead’s funding of Lyndra’s technology, the latter company offers exclusive rights to its therapeutics platform for long-acting HIV therapies formulations.

The partnership between the two companies began when Gilead Sciences joined Lyndra Therapeutics' $55m (€49m) Series B financing round in January 2019​, along with the Bill & Melinda Gates Foundation and other organisations. 

The two companies have now announced a collaboration, under which they will work together to develop and commercialize oral HIV therapies, with Gilead gaining exclusive rights to Lyndra’s therapeutics platform for long-acting formulations.

Speaking about “potential strategies for long-acting regimens that would reduce pill burden”​, Gilead’s CSO, John McHutchison said that “this early partnership is the latest step in our ongoing investment in HIV research and development.”

Lyndra’s star-shaped pill

Lyndra Therapeutics, a Massachusetts, US-based MIT spin-out, has designed a capsule in a star-shaped formulation, which opens once inside the stomach, releasing active pharmaceutical ingredients (APIs) consistently over time before exiting via the gastrointestinal tract.

This orally administered dosage form aims to deliver sustained, steady-state release of one or more drugs for up to a week or longer while temporarily residing in the stomach.

By turning daily treatments into weekly or monthly doses, the formulation is expected to reduce side-effects and healthcare costs while improving medication adherence and drug efficacy.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more